摘要
目的研究TEL-AML1融合基因在儿童急性淋巴细胞白血病(ALL)的发生率及其临床意义。方法在MIC分型(形态学、免疫学、细胞遗传学)基础上,采用巢式逆转录-聚合酶链反应(RT-PCR)检测ALL患儿90例TEL-AML1融合基因。结果TEL-AML1融合基因在初发ALL儿童中的阳性率为22.2%(20/90),在B系ALL中的阳性率为23.7%(19/80)。1例T系ALL患儿融合基因阳性。TEL-AML1融合基因阳性和阴性患儿化疗d15完全缓解率、复发率和早期死亡率比较无显著性差异。结论TEL-AML1融合基因阳性患儿的近期治疗效果未优于该融合基因阴性患儿。
Objective To study the frequency and clinical significance of transloation,ets,leukemia-acute myeloblasticleukemia1 （TEL-AML1） fusion gene in children with acute lymphoblastic leukemia （ALL）.Methods Base on MIC（morphology,immunology and cytogenetics）,nested reverse transiption-polymerase chain reaction（RT-PCR） was performed to detect TEL-AML1 fusion gene.Results TEL-AML1 fusion gene was found in 22.2% （20/90） of patients with newly diagnosed ALL and 23.7% （19/80） in B lineage ALL cases.The fusion gene was found in 1 T lineage ALL case.Fifteenth days′ complete remission rate and early mortality were no difference between TEL-AML1 fusion gene positive group and negative group.Conclusion Therapeutic results are not different between TEL-AML1 fusion gene positive group and negative group lately.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2007年第3期191-192,194,共3页
Journal of Applied Clinical Pediatrics
关键词
白血病
淋巴细胞
急性
儿童
聚合酶链反应
TEL-AML1融合基因
leukemia,lymphoblastic,acute,child,polymerase chain reaction,transloation,ets,leukemia,acute myeloblasticleukeia1 fusion gene
